"Latest News" Archive2003 - 2004 - 2005 - 2006 - 2007 - 2008 - 2009 - 2010
2011
May 3, 2011: National Children's Mental Health Awareness Day: Connect the Dots: Understanding Children's Mental Health. See NIMH's featured publication on ADHD
April 19, 2011: FDA's list of Medication Guides includes guides for most ADHD medications
April 11, 2011: FDA adds major ADHD medications to Current Drug Shortages (see CHADD's Leadership Blog)
April 1, 2011: Artificial Food Dyes and ADHD -- What does CHADD think?
March 26, 2011: FDA announces voluntary recall of citalopram from Greenstone, LLC due to possible mislabeling.
March 15, 2011: FDA warns: Beware of Fraudulent "Dietary Supplements."
Feb. 25, 2011: FDA approves Intuniv ER tablets as adjunctive treamtent to stimulants.
Jan. 7, 2011: CDC announces January is National Birth Defects Prevention Month.
Nov. 10, 2010: CDC reports an increasing rate of parent-reported ADHD in U.S. children. See CHADD's statement.
Oct. 14, 2010: The FDA is tightening the reins on unproven "chelation" drugs, saying that over-the-counter medications have not been approved for chelation therapy.
Sept. 28, 2010: FDA approves Kapvay (clonidine HCL extended release tablets) for treatment of ADHD.
Sept. 15, 2010: NIMH Director's Blog Recognizes ADHD Awareness Week
Sept. 14, 2010: "Does my child have ADHD?" - NIMH Video on signs, symptoms and research.
Sept. 13, 2010: CHADD supports ADHD Awareness Week, September 13 - 17, 2010!
July 9, 2010: FDA approves Daytrana (methylphenidate) transdermal systems to treat ADHD for 13-17 year olds.
June 30, 2010: FDA issues Warning Letter about certain Intuniv marketing materials
June 3, 2010: CDC Reports 1 in 5 US HS students have abused prescription drugs (including ADHD medications)
May 18, 2010: View CHADD's statement on ADHD and Pesticides
May 6, 2010: CHADD supports National Children's Mental Health Awareness Day
Dec 14. 2009: NIH and NIMH release data from survey that tracks rates of common mental disorders among American youth
Sept. 29, 2009: NIH's Consumer Health Information Request for Information (RFI) helps disseminate science-based health resources to public
Sept. 16, 2009: FDA issues "Tentative Approval" for atomoxetine hydrochloride (generic of Strattera)
Sept. 2, 2009: FDA approves Intuniv (guanfacine) extended-release treating ADHD in children 6-17 yrs
June 23, 2009: FDA and NIMH statements about ADHD medications and sudden death
June 2, 2009: FDA Promotes Openness and Transparency to Public
May 1, 2009: New NIMH study shows ADHD Medication Treatment Associated with Higher Academic Performance in Elementary School
Apr. 30, 2009: FDA's updated Public Health Advisory on Strattera and Suicidal Thinking
April 27, 2009: ADHD Medication Treatment Associated with Higher Academic Performance in Elementary School
Apr. 16, 2009: FDA information sheet on Clinical Trials and Institutional Review Boards (IRB)
Jan. 16, 2009: FDA Drug Safety Newsletter with warning on possible liver damage from Atomoxetine (Strattera)
Nov 2008: DSM-V Work Group on ADHD Issues Report
Nov. 19, 2008: NIH Study: ADHD Medications Do Not Cause Genetic Damage in Children
Oct. 16, 2008: FDA Announces Voluntary Recall of ADHD Medication by ETHEX Corp
Aug. 14, 2008: FDA Updates Strattera Safety Label; Issues Warning Letter on Marketing Statements (9/29/08)
Aug. 14, 2008: NIMH Releases new Booklet on ADHD
July 29, 2008: FDA Issues Revised Label and Updated Medication Guide (pdf) for Concerta®
July 23, 2008: Vital and Health Statistics Report (pdf) on ADHD Prevalence (CDC/NCHS)
June 5, 2008: New NIMH Research to Test Innovative Treatments for Children with ADHD
June 2, 2008: NIMH Funds Research to Find Best Treatments for Children with Autism and ADHD Symptoms
April 21, 2008: CHADD's Position on AHA Call for Cardiac Screening
April 16, 2008: NIMH Director Dr. Thomas Insel Blogs for CHADD on ADHD Research Priorities
April 14, 2008: JCAHO Issues "Alert" to Prevent Pediatric Medication Errors
April 3, 2008: NIH Research Suggests Stimulant Treatment for ADHD Does Not Contribute to Substance Abuse Later in Life
March 5, 2008: National Survey on Drug Use and Health (NSDUH) Report: Nonmedical Stimulant Use, Other Drug Use, Delinquent Behaviors, and Depression Among Adolescents
Feb. 20, 2008: FDA Proposes Guidance for Dissemination of Information on Unapproved Uses of Medical Products.
Nov. 19, 2007: DEA Rule permits 90-day supply of Schedule II prescriptions (CHADD statement
Nov. 12, 2007: NIMH reports brain matures late in ADHD; follows normal pattern)
Nov. 5, 2007: NIMH study finds preschoolers with 3+ coexisting disorders do not respond to ADHD meds
Aug. 15, 2007: NIMH study finds behavioral interventions effective for preschoolers with ADHD
July 20, 2007: NIMH Issues Follow Up to Major ADHD Study (the MTA Study); CHADD Comments
July 16, 2007: Child & Adolescent Psychiatrists Issue New Practice Parameter
June 22, 2007: FDA Issues Dietary Supplements Final Rule
March 21, 2007: FDA Proposes New, Tougher Procedures for Membership on Advisory Committees
Feb. 23, 2007: FDA Issues Approval for Vyvanse
Feb. 21, 2007: FDA Directs ADHD Drug Manufacturers to Develop Patient Medication Guides
Jan. 30, 2007: FDA Statement on Commitment to Drug Safety
Jan. 29, 2007: CHADD and Other Advocates Issue Joint Statement on Improving the Mental Health and Well-Being of America's Children
Dec. 4, 2006: Statement of CHADD PAB on Environmental Factors and ADHD
Oct. 16, 2006: NIMH Press Release: Preschoolers with ADHD and Low Doses of Medication
Sept. 22, 2006: SAMHSA's DAWN Report on Emergency Room Visits and ADHD Stimulant Medications
Aug. 21, 2006: FDA and GlaxoSmithKline Notify Health Professionals of Prescribing Changes for Dexedrine (dextroamphetamine sulfate)
Aug. 8, 2006: Novartis's FDA-approved Revised Label for Ritalin Products
June 1, 2006: GRATIS Guia Bilingüe Ahora Disponible // FREE Bilingual Education Guide Now Available
May 26, 2006: Health Canada Advisory on Rare Risks for ADHD Medications
Feb. 14, 2006: CHADD Statement on Meeting of FDA Advisory Committee Recommendation
Oct. 24, 2005: FDA Orders Discontinuation of Cylert (pemoline)
Sep. 29, 2005: FDA Issues Public Health Advisory on Strattera (atomoxetine)
Aug. 24, 2005: Health Canada allows Adderall XR back on Canadian market
Aug. 11, 2005: Transcript of FDA Pediatric Advisory Committee 6/30/05 Meeting re: Medication Labeling Changes
Feb. 10, 2005: Canada Suspends Sales of Adderall XR; Statement by FDA
Jan. 14, 2005: One Lot of Methylin Voluntarily Recalled
Dec. 2004: "Black Box" Warning (from Attention! magazine)
Dec. 17, 2004: FDA Issues Talk Paper, New Warning About Strattera
Oct. 15, 2004: FDA Issues Public Health Advisory on Antidepressants and Children
Aug. 20, 2004: FDA Talk Paper Use of Antidepressant Medications for Children
July, 2004: FDA seeks Patient Representatives for Advisory Committee on ADHD
April 5, 2004: Pediatrics study on TV Viewing and Attentional Problems
March 22, 2004: FDA Issues Advisory on Antidepressant Use
March 17, 2004: Federal Trade Commission Fines "Focus Factor" $1M - (for related info)
Dec. 18, 2003: NRC Launches Online Library
May 20, 2003: The National Resource Center on ADHD Holds Grand Opening Ceremony
|
